Tonglei  Li

Dr. Tonglei Li


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2022 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
JDJiaxing Di
Jiaxing Di
ZDZhili Du
Zhili Du
KWKangzeng Wu
Kangzeng Wu
SJShanshan Jin
Shanshan Jin
XWXun Wang
Xun Wang
YXYuhong Xu
Yuhong Xu

1 November 2013 in Journal of Controlled Release
Verified
Journal Article
Closed access
CHChristin P. Hollis
Christin P. Hollis
HWHeidi L. Weiss
Heidi L. Weiss
MLMarkos Leggas
Markos Leggas
BEB. Mark Evers
B. Mark Evers
RGRichard A. Gemeinhart
Richard A. Gemeinhart
TLTonglei Li
Tonglei Li

21 August 2015 in Nanomedicine
Verified
Journal Article
Closed access
Yi Lu, Ph.D.Yi Lu, Ph.D.
Yi Lu, Ph.D.
YCYan Chen
Yan Chen
RGRichard A Gemeinhart
Richard A Gemeinhart
Wei WuWei Wu
Wei Wu
TLTonglei Li
Tonglei Li
Nanocrystals are carrier-free solid drug particles that are sized in the nanometer range and have crystalline characteristics. Due to high drug loading (as high as 100%) – free of organic solvents or solubilizing chemicals – nanocrystals have become attractive in the field of drug delivery for cancer treatment. Top–down and bottom–up approaches have been developed for preparing anticancer nanocrystals. In this review, preparation methods and in vivo performance of anticancer nanocrystals are discussed first, followed by an introduction of hybrid nanocrystals in cancer theranostics.

1 March 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Yi Lu, Ph.D.Yi Lu, Ph.D.
Yi Lu, Ph.D.
YLYongjiu Lv
Yongjiu Lv
TLTonglei Li
Tonglei Li

9 February 2022 in Polymers
Verified
Journal Article
Open access
PDF file
RHRazan Haddad
Razan Haddad
NANasr Alrabadi
Nasr Alrabadi
BABashar M Altaani
Bashar M Altaani
TLTonglei Li
Tonglei Li
Paclitaxel (PTX) is a chemotherapeutic agent that belongs to the taxane family and which was approved to treat various kinds of cancers including breast cancer, ovarian cancer, advanced non-small-cell lung cancer, and acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma. Several delivery systems for PTX have been developed to enhance its solubility and pharmacological properties involving liposomes, nanoparticles, microparticles, micelles, cosolvent methods, and the complexation with cyclodextrins and other materials that are summarized in this article. Specifically, this review discusses deeply the developed paclitaxel nanocrystal formulations. As PTX is a hydrophobic drug with inferior water solubility properties, which are improved a lot by nanocrystal formulation. Based on that, many studies employed nano-crystallization techniques not only to improve the oral delivery of PTX, but IV, intraperitoneal (IP), and local and intertumoral delivery systems were also developed. Additionally, superior and interesting properties of PTX NCs were achieved by performing additional modifications to the NCs, such as stabilization with surfactants and coating with polymers. This review summarizes these delivery systems by shedding light on their route of administration, the methods used in the preparation and modifications, the in vitro or in vivo models used, and the advantages obtained based on the developed formulations.

26 April 2013 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
CHChristin P. Hollis
Christin P. Hollis
HWHeidi L. Weiss
Heidi L. Weiss
BEB. Mark Evers
B. Mark Evers
RGRichard A. Gemeinhart
Richard A. Gemeinhart
TLTonglei Li
Tonglei Li